Key facts: BSX Q3; EPS cut; China, EP/Watchman weak; Penumbra Q1'27
Boston Scientific (BSX) reported Q3 sales of $5.138B, up 1.5% YoY, with adjusted EPS of $0.73. The company cut FY2026 adjusted EPS guidance to $3.16–3.18, citing China pricing pressure and weakness in EP/Watchman devices. BSX expects Q4 sales to decline 1%–3%. The $14.5B Penumbra acquisition is delayed to Q1 2027 due to regulatory and financing issues. Needham maintained a Buy rating with a $48 target.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to trigger a sell‑off, while the announced acquisition adds a layer of financing risk.
Market read
First‑time disclosure of earnings miss, guidance cut, and a large acquisition makes this a high‑impact earnings story for BSX and the med‑tech sector.
What to watch
Potential upside from Farapulse and Watchman product lines if they recover, and any cost‑saving measures from the acquisition.
Background
Boston Scientific is a leading medical device maker; its Q3 results and FY guidance are closely watched by investors.
Ticker impact
Boston Scientific reported Q3 sales of $5.138B, GAAP EPS $0.40 and cut FY2026 adjusted EPS guidance to $3.16‑$3.18, plus disclosed a $14.5B Penumbra acquisition closing in Q1 2027.
likely downside pressure as investors price in lower EPS guidance and higher financing costs from the Penumbra deal
The EPS guidance cut is material for a large‑cap med‑tech company; the acquisition adds financing drag, both new facts disclosed for the first time.
Market effects
Med‑tech sector may see broader pressure as peers reassess growth outlook amid pricing headwinds in China.
China pricing pressure could affect other US med‑device firms with exposure to APAC.
Large‑cap earnings and M&A activity may influence global healthcare indices.
Counterpoint
If the Penumbra acquisition yields synergies faster than expected, the stock could rebound despite short‑term earnings drag.
Key entities
- CompanyBoston Scientific
US‑listed medical device manufacturer (ticker BSX).
- Target CompanyPenumbra
Medical device firm being acquired for $14.5B.
